Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia

Next Previous
Trial Profile

Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Thrombocytopenia
  • Focus Therapeutic Use

Most Recent Events

  • 12 Dec 2017 Results (n=10) of a pilot study using eculizumab to overcome platelet transfusion refractoriness in allo-immunized patients receiving hla mismatched platelets, were presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
  • 09 Aug 2017 Status changed from recruiting to completed.
  • 06 Dec 2016 Preliminary results (n=7) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top